Alyeska Investment Group, L.P. Aurinia Pharmaceuticals Inc. Transaction History

Alyeska Investment Group, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 14, 2018	SELL	$5.06 - $6.36 $1.96 Million - $2.47 Million	-387,615 Reduced 67.26%	188,709 $1.06 Million
Q1 2018 May 15, 2018	SELL	$4.85 - $5.99 $25,186 - $31,106	-5,193 Reduced 0.89%	576,324 $2.99 Million
Q4 2017 Feb 14, 2018	SELL	$4.53 - $7.09 $453,000 - $709,000	-100,000 Reduced 14.67%	581,517 $2.63 Million
Q3 2017 Nov 14, 2017	BUY	$5.71 - $6.9 $3.89 Million - $4.7 Million	681,517	681,517 $4.27 Million

230

58.9M

949K

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.1B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

Stay updated on Alyeska Investment Group, L.P. with notifications on news.